EphA2 Antibody (Kα-5H5): sc-101377

EphA2 Antibody (Kα-5H5) is a mouse monoclonal IgG1 light chain antibody that detects EphA2 in human samples through applications such as immunofluorescence (IF), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). EphA2 is a member of the Eph receptor family, which represents the largest group of receptor protein tyrosine kinases identified to date, playing a crucial role in various biological processes, including cell adhesion, migration, and differentiation. EphA2 is predominantly located on the cell surface, where EphA2 interacts with ephrin-A2 and ephrin-B1 to mediate bidirectional signaling essential for nervous system development and angiogenesis regulation. Proper functioning of EphA2 is vital, as dysregulation has been implicated in several pathological conditions, including cancer progression and metastasis. Anti-EphA2 antibody (Kα-5H5) provides a valuable tool for researchers aiming to explore signaling pathways involving EphA2 and its ligands, facilitating a deeper understanding of EphA2′s role in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

EphA2 Antibody (Kα-5H5) References:

1. Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex.  |  Fattet, L., et al. 2020. Dev Cell. 54: 302-316.e7. PMID: 32574556
2. Oncogenic functions and therapeutic targeting of EphA2 in cancer.  |  Wilson, K., et al. 2021. Oncogene. 40: 2483-2495. PMID: 33686241
3. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.  |  Gai, QJ., et al. 2022. Signal Transduct Target Ther. 7: 33. PMID: 35105853
4. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling.  |  Han, B., et al. 2022. Theranostics. 12: 4127-4146. PMID: 35673569
5. Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis.  |  Yan, H., et al. 2023. Nat Commun. 14: 2756. PMID: 37179400
6. Claudin-1 interacts with EPHA2 to promote cancer stemness and chemoresistance in colorectal cancer.  |  Primeaux, M., et al. 2023. Cancer Lett. 579: 216479. PMID: 37924938
7. Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly.  |  Shi, X., et al. 2023. Science. 382: 1042-1050. PMID: 37972196
8. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.  |  Joseph, R., et al. 2024. Int J Mol Sci. 25: PMID: 38279277
9. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/AKT signaling pathway.  |  Li, A., et al. 2024. Cell Death Dis. 15: 235. PMID: 38531846
10. EphA2 promotes the transcription of KLF4 to facilitate stemness in oral squamous cell carcinoma.  |  Bai, J., et al. 2024. Cell Mol Life Sci. 81: 278. PMID: 38916835

The preferred EphA2 antibody is EphA2 Antibody (C-3): sc-398832.